Accuray (ARAY) Projected to Post Earnings on Wednesday

Accuray (NASDAQ:ARAY) is projected to announce its Q1 2027 results after the market closes on Wednesday, November 4th. Analysts expect Accuray to announce earnings of ($0.07) per share and revenue of $95.80 million for the quarter. Interested persons may visit the company’s upcoming Q1 2027 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last announced its earnings results on Wednesday, August 19th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The business had revenue of $100.92 million for the quarter, compared to analysts’ expectations of $105.30 million. Accuray had a negative return on equity of 97.85% and a negative net margin of 12.24%.

Accuray Trading Up 5.7%

Accuray stock opened at $0.15 on Tuesday. The business has a 50-day simple moving average of $0.22 and a two-hundred day simple moving average of $0.37. The company has a market cap of $17.69 million, a P/E ratio of -0.37 and a beta of 1.42. Accuray has a 52-week low of $0.12 and a 52-week high of $1.46. The company has a quick ratio of 0.74, a current ratio of 1.50 and a debt-to-equity ratio of 3.51.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Weiss Ratings lowered shares of Accuray from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 1st. BTIG Research dropped coverage on shares of Accuray in a report on Wednesday, July 8th. They set a “neutral” rating for the company. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce”.

Accuray Company Profile

Accuray Incorporated develops, manufactures and supports radiation oncology systems used to treat cancer. The company focuses on precision radiotherapy technologies designed to deliver targeted radiation while helping clinicians manage treatment complexity and limit exposure to surrounding healthy tissue.

Its principal product platforms include the CyberKnife System, a robotic, image-guided radiation therapy system used for radiosurgery and stereotactic body radiation therapy, and the Radixact System, an image-guided tomotherapy platform designed to deliver highly conformal radiation treatments.